The 3 main considerations for NESTLÉ^® selecting the 2 HMOs 2’FL and LNnT are as follows:

• Firstly, 2’FL and LNnT are among the 10 most abundant HMOs. ^1-3 2’FL is the most abundant HMO in human breast milk, contributing tonabout 30 % of all HMOs in the breast milk of most women. ^1-3 LNnT constitutes 2 % to 3 % of the total HMO fraction in human breast milk. ²
• Secondly, the 2 HMOs 2’FL and LNnT are the most researched HMOs in preclinical and clinical studies, providing evidence for positive effects on immunity and safety^4-8. NESTLÉ^® has been pioneering HMO research activities for more than 30 years with several preclinical and clinical studies related to 2’FL and LNnT. ^4-6
• Thirdly, and most importantly, 2’FL and LNnT were approved as safe by the EFSA ^9,10 and the US FDA. ^11-13